Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma

ASCO Direct Highlights™ 2022 Miami Symposium

Published: 9 Jul 2022

Views: 157

Rating:

Save

Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA

Dr Eduardo Sotomayor speaks to ecancer about the advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma.

He initially, talks about the main study from ASCO 2022 regarding the treatment of stage III and IV of Hodgkin lymphoma with a new antibody-drug conjugate.

Dr Sotomayor also discusses new combination therapies for patients with relapsed Hodgkin lymphoma. He further discusses bispecific antibodies for treating non-Hodgkin lymphoma.

He concludes by talking about the treatment strategies he uses to treat lymphoma patients.

Related Videos

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

More from ecancer